Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus | 68 | 2023 | 801 | 17.570 |
Why?
|
Endocrinology | 16 | 2022 | 66 | 11.790 |
Why?
|
Diabetes Mellitus, Type 2 | 63 | 2023 | 1372 | 10.160 |
Why?
|
Hypoglycemic Agents | 36 | 2023 | 377 | 5.750 |
Why?
|
Blood Glucose | 48 | 2024 | 873 | 5.740 |
Why?
|
Diabetes Mellitus, Type 1 | 20 | 2024 | 566 | 4.390 |
Why?
|
Medicaid | 11 | 2022 | 216 | 4.080 |
Why?
|
Aging | 23 | 2023 | 689 | 4.060 |
Why?
|
Blood Glucose Self-Monitoring | 13 | 2022 | 57 | 3.320 |
Why?
|
Standard of Care | 16 | 2022 | 78 | 3.190 |
Why?
|
Reference Standards | 16 | 2022 | 159 | 3.170 |
Why?
|
Diabetes Complications | 19 | 2023 | 206 | 2.920 |
Why?
|
Community Health Centers | 14 | 2023 | 113 | 2.900 |
Why?
|
Hypoglycemia | 18 | 2023 | 106 | 2.650 |
Why?
|
Societies, Medical | 16 | 2022 | 572 | 2.540 |
Why?
|
Humans | 213 | 2024 | 86281 | 2.480 |
Why?
|
Aged | 100 | 2023 | 18353 | 2.480 |
Why?
|
United States | 70 | 2023 | 6637 | 2.360 |
Why?
|
Healthcare Disparities | 13 | 2016 | 369 | 2.340 |
Why?
|
Cost-Benefit Analysis | 22 | 2022 | 450 | 2.290 |
Why?
|
Insulin | 16 | 2023 | 1159 | 2.020 |
Why?
|
Quality of Life | 21 | 2023 | 1575 | 1.780 |
Why?
|
Cardiovascular Diseases | 12 | 2023 | 826 | 1.740 |
Why?
|
Female | 122 | 2023 | 44405 | 1.740 |
Why?
|
Male | 116 | 2023 | 40860 | 1.700 |
Why?
|
Primary Health Care | 13 | 2022 | 339 | 1.690 |
Why?
|
Middle Aged | 90 | 2023 | 24957 | 1.670 |
Why?
|
Quality-Adjusted Life Years | 13 | 2022 | 138 | 1.420 |
Why?
|
Patient Protection and Affordable Care Act | 5 | 2022 | 66 | 1.330 |
Why?
|
Insurance, Health | 5 | 2016 | 158 | 1.270 |
Why?
|
Insurance Coverage | 6 | 2019 | 115 | 1.270 |
Why?
|
Ambulatory Care Facilities | 6 | 2022 | 102 | 1.250 |
Why?
|
Adult | 70 | 2023 | 25577 | 1.240 |
Why?
|
Aged, 80 and over | 32 | 2023 | 6481 | 1.150 |
Why?
|
Quality Improvement | 7 | 2022 | 423 | 1.140 |
Why?
|
Health Services for the Aged | 3 | 2015 | 27 | 1.140 |
Why?
|
Health Expenditures | 4 | 2016 | 86 | 1.120 |
Why?
|
Comorbidity | 16 | 2022 | 943 | 1.100 |
Why?
|
Health Status | 10 | 2023 | 360 | 1.080 |
Why?
|
Decision Support Techniques | 4 | 2016 | 160 | 1.050 |
Why?
|
Cross-Sectional Studies | 21 | 2021 | 1610 | 1.030 |
Why?
|
Delivery of Health Care | 7 | 2023 | 423 | 1.030 |
Why?
|
Appointments and Schedules | 2 | 2019 | 53 | 1.000 |
Why?
|
Precision Medicine | 4 | 2019 | 394 | 0.960 |
Why?
|
Health Status Disparities | 5 | 2016 | 170 | 0.950 |
Why?
|
Frailty | 2 | 2021 | 56 | 0.940 |
Why?
|
Insulin Infusion Systems | 4 | 2023 | 36 | 0.930 |
Why?
|
Chronic Disease | 5 | 2016 | 968 | 0.910 |
Why?
|
Eligibility Determination | 3 | 2022 | 31 | 0.900 |
Why?
|
Safety-net Providers | 5 | 2019 | 37 | 0.900 |
Why?
|
Patient-Centered Care | 10 | 2022 | 202 | 0.880 |
Why?
|
Minority Groups | 3 | 2016 | 132 | 0.880 |
Why?
|
Dementia | 7 | 2023 | 187 | 0.870 |
Why?
|
Adolescent | 28 | 2022 | 8968 | 0.870 |
Why?
|
Quality of Health Care | 8 | 2022 | 380 | 0.870 |
Why?
|
Health Care Costs | 6 | 2023 | 237 | 0.850 |
Why?
|
Patient Acceptance of Health Care | 4 | 2023 | 237 | 0.850 |
Why?
|
Risk Factors | 24 | 2023 | 5397 | 0.830 |
Why?
|
Patient Satisfaction | 7 | 2012 | 452 | 0.830 |
Why?
|
Risk Assessment | 11 | 2023 | 2253 | 0.810 |
Why?
|
Longitudinal Studies | 12 | 2022 | 1015 | 0.800 |
Why?
|
Hospitalization | 7 | 2020 | 844 | 0.790 |
Why?
|
Medication Adherence | 3 | 2019 | 129 | 0.790 |
Why?
|
Obesity | 5 | 2023 | 962 | 0.790 |
Why?
|
Genetic Testing | 3 | 2019 | 535 | 0.770 |
Why?
|
Retinal Diseases | 1 | 2022 | 90 | 0.770 |
Why?
|
Disabled Persons | 1 | 2021 | 67 | 0.760 |
Why?
|
United States Department of Veterans Affairs | 3 | 2019 | 26 | 0.760 |
Why?
|
Young Adult | 24 | 2021 | 5961 | 0.750 |
Why?
|
Children's Health Insurance Program | 1 | 2020 | 2 | 0.740 |
Why?
|
Public Sector | 1 | 2020 | 12 | 0.740 |
Why?
|
Private Sector | 1 | 2020 | 19 | 0.730 |
Why?
|
Cohort Studies | 17 | 2023 | 2759 | 0.730 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2017 | 57 | 0.720 |
Why?
|
Financing, Personal | 2 | 2016 | 21 | 0.720 |
Why?
|
Comparative Effectiveness Research | 2 | 2023 | 53 | 0.710 |
Why?
|
Hypertension | 5 | 2017 | 1139 | 0.710 |
Why?
|
Polypharmacy | 3 | 2016 | 15 | 0.710 |
Why?
|
Life Expectancy | 7 | 2023 | 85 | 0.680 |
Why?
|
Child | 19 | 2024 | 6913 | 0.680 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 350 | 0.670 |
Why?
|
Residence Characteristics | 3 | 2017 | 195 | 0.660 |
Why?
|
Physicians | 4 | 2019 | 672 | 0.650 |
Why?
|
Odds Ratio | 7 | 2015 | 677 | 0.630 |
Why?
|
Frail Elderly | 4 | 2021 | 71 | 0.610 |
Why?
|
Quality Assurance, Health Care | 6 | 2012 | 220 | 0.600 |
Why?
|
Geriatric Assessment | 4 | 2021 | 166 | 0.590 |
Why?
|
Public Health | 2 | 2012 | 129 | 0.580 |
Why?
|
Hypercholesterolemia | 2 | 2017 | 161 | 0.580 |
Why?
|
Telemedicine | 1 | 2019 | 168 | 0.570 |
Why?
|
Follow-Up Studies | 13 | 2019 | 3616 | 0.570 |
Why?
|
Child Health Services | 1 | 2016 | 49 | 0.570 |
Why?
|
Physicians, Primary Care | 2 | 2015 | 104 | 0.560 |
Why?
|
Nutrition Surveys | 5 | 2022 | 114 | 0.560 |
Why?
|
Health Services Needs and Demand | 2 | 2016 | 102 | 0.560 |
Why?
|
Electronic Health Records | 8 | 2023 | 319 | 0.550 |
Why?
|
Home Care Services | 1 | 2017 | 72 | 0.550 |
Why?
|
Drug Labeling | 1 | 2015 | 41 | 0.540 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 378 | 0.540 |
Why?
|
Physicians, Family | 2 | 2008 | 40 | 0.540 |
Why?
|
California | 10 | 2016 | 138 | 0.530 |
Why?
|
Thiazolidinediones | 1 | 2015 | 82 | 0.530 |
Why?
|
Health Policy | 2 | 2015 | 180 | 0.530 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 127 | 0.520 |
Why?
|
Diabetic Foot | 4 | 2019 | 13 | 0.520 |
Why?
|
Drug Costs | 4 | 2021 | 62 | 0.510 |
Why?
|
Practice Patterns, Physicians' | 2 | 2015 | 578 | 0.510 |
Why?
|
Body Mass Index | 7 | 2023 | 770 | 0.510 |
Why?
|
Forecasting | 3 | 2013 | 303 | 0.510 |
Why?
|
Logistic Models | 9 | 2019 | 1184 | 0.510 |
Why?
|
Medically Underserved Area | 2 | 2022 | 25 | 0.510 |
Why?
|
Blood Pressure | 8 | 2019 | 1143 | 0.510 |
Why?
|
Monitoring, Ambulatory | 5 | 2018 | 32 | 0.510 |
Why?
|
Retrospective Studies | 18 | 2023 | 8431 | 0.510 |
Why?
|
Socioeconomic Factors | 9 | 2017 | 567 | 0.490 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2023 | 850 | 0.490 |
Why?
|
Glucagon-Like Peptide-1 Receptor | 3 | 2023 | 35 | 0.490 |
Why?
|
Federal Government | 2 | 2014 | 29 | 0.490 |
Why?
|
Preventive Health Services | 1 | 2014 | 37 | 0.480 |
Why?
|
Registries | 6 | 2020 | 702 | 0.480 |
Why?
|
Office Visits | 2 | 2017 | 44 | 0.470 |
Why?
|
Medicare | 6 | 2020 | 404 | 0.470 |
Why?
|
Heart Transplantation | 4 | 2020 | 705 | 0.470 |
Why?
|
Health Care Reform | 2 | 2015 | 90 | 0.460 |
Why?
|
Costs and Cost Analysis | 4 | 2023 | 153 | 0.460 |
Why?
|
Age Factors | 10 | 2021 | 1842 | 0.460 |
Why?
|
Referral and Consultation | 3 | 2021 | 326 | 0.450 |
Why?
|
Decision Making | 2 | 2016 | 641 | 0.450 |
Why?
|
Gastrointestinal Agents | 2 | 2021 | 161 | 0.450 |
Why?
|
Models, Theoretical | 2 | 2013 | 480 | 0.450 |
Why?
|
Pediatrics | 1 | 2016 | 344 | 0.430 |
Why?
|
Myocardial Infarction | 1 | 2015 | 372 | 0.430 |
Why?
|
Disease Management | 5 | 2016 | 327 | 0.430 |
Why?
|
Language | 1 | 2014 | 151 | 0.430 |
Why?
|
Health Services Research | 6 | 2017 | 135 | 0.420 |
Why?
|
Surveys and Questionnaires | 11 | 2021 | 2495 | 0.420 |
Why?
|
Caregivers | 2 | 2023 | 151 | 0.420 |
Why?
|
Incidence | 10 | 2017 | 1568 | 0.420 |
Why?
|
Program Evaluation | 3 | 2014 | 297 | 0.420 |
Why?
|
Bariatric Surgery | 2 | 2014 | 194 | 0.420 |
Why?
|
Depression | 6 | 2013 | 472 | 0.410 |
Why?
|
Models, Biological | 1 | 2019 | 1748 | 0.410 |
Why?
|
Health Services Accessibility | 7 | 2022 | 392 | 0.410 |
Why?
|
Urinary Incontinence | 1 | 2013 | 200 | 0.400 |
Why?
|
Biomarkers | 6 | 2019 | 1709 | 0.390 |
Why?
|
Total Quality Management | 2 | 2008 | 34 | 0.390 |
Why?
|
Prevalence | 7 | 2017 | 1239 | 0.390 |
Why?
|
Program Development | 2 | 2007 | 124 | 0.370 |
Why?
|
Databases, Factual | 3 | 2019 | 808 | 0.370 |
Why?
|
Chicago | 8 | 2020 | 1377 | 0.370 |
Why?
|
Physician-Patient Relations | 4 | 2016 | 610 | 0.360 |
Why?
|
Health Surveys | 5 | 2021 | 238 | 0.360 |
Why?
|
Pancreatic Cyst | 1 | 2009 | 28 | 0.360 |
Why?
|
Data Accuracy | 2 | 2023 | 31 | 0.360 |
Why?
|
Population Density | 1 | 2009 | 60 | 0.350 |
Why?
|
Accidental Falls | 1 | 2009 | 50 | 0.350 |
Why?
|
Health Facility Administrators | 2 | 2010 | 15 | 0.350 |
Why?
|
Markov Chains | 4 | 2021 | 125 | 0.340 |
Why?
|
Cost of Illness | 1 | 2009 | 150 | 0.340 |
Why?
|
Self Care | 5 | 2013 | 164 | 0.340 |
Why?
|
Burnout, Professional | 4 | 2019 | 93 | 0.340 |
Why?
|
Mass Screening | 4 | 2019 | 615 | 0.330 |
Why?
|
Professional-Patient Relations | 3 | 2014 | 53 | 0.330 |
Why?
|
Drug Therapy | 1 | 2008 | 70 | 0.330 |
Why?
|
Emergency Service, Hospital | 3 | 2018 | 484 | 0.330 |
Why?
|
Hospitals | 2 | 2022 | 290 | 0.320 |
Why?
|
Rifamycins | 1 | 2007 | 5 | 0.320 |
Why?
|
Genomics | 1 | 2013 | 710 | 0.320 |
Why?
|
Lactulose | 1 | 2007 | 18 | 0.310 |
Why?
|
Quality Indicators, Health Care | 3 | 2020 | 144 | 0.310 |
Why?
|
Patient Education as Topic | 2 | 2016 | 351 | 0.310 |
Why?
|
Diabetic Retinopathy | 3 | 2016 | 84 | 0.310 |
Why?
|
Hepatic Encephalopathy | 1 | 2007 | 39 | 0.310 |
Why?
|
Attitude of Health Personnel | 7 | 2019 | 636 | 0.310 |
Why?
|
Laboratories, Hospital | 1 | 2007 | 7 | 0.310 |
Why?
|
Financial Management | 1 | 2007 | 21 | 0.310 |
Why?
|
Treatment Outcome | 11 | 2019 | 7949 | 0.310 |
Why?
|
Prescription Drugs | 2 | 2020 | 36 | 0.300 |
Why?
|
Morale | 4 | 2019 | 14 | 0.300 |
Why?
|
Preoperative Care | 1 | 2009 | 390 | 0.300 |
Why?
|
Liver Failure | 1 | 2007 | 78 | 0.300 |
Why?
|
Infant | 4 | 2021 | 3036 | 0.300 |
Why?
|
Health Plan Implementation | 1 | 2007 | 56 | 0.300 |
Why?
|
Patient Care Management | 2 | 2011 | 31 | 0.300 |
Why?
|
Monte Carlo Method | 3 | 2017 | 185 | 0.290 |
Why?
|
Job Satisfaction | 3 | 2019 | 73 | 0.290 |
Why?
|
Time Factors | 8 | 2019 | 5198 | 0.280 |
Why?
|
Metformin | 2 | 2022 | 128 | 0.280 |
Why?
|
Clinical Decision-Making | 2 | 2019 | 255 | 0.280 |
Why?
|
Attitude to Health | 3 | 2016 | 220 | 0.270 |
Why?
|
Monitoring, Physiologic | 1 | 2007 | 268 | 0.270 |
Why?
|
Anti-Bacterial Agents | 3 | 2013 | 739 | 0.270 |
Why?
|
Goals | 2 | 2006 | 67 | 0.270 |
Why?
|
Predictive Value of Tests | 5 | 2012 | 1671 | 0.260 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 1030 | 0.260 |
Why?
|
Colorado | 3 | 2021 | 35 | 0.260 |
Why?
|
Tissue and Organ Procurement | 2 | 2020 | 310 | 0.260 |
Why?
|
Interviews as Topic | 6 | 2016 | 319 | 0.260 |
Why?
|
Self-Assessment | 1 | 2005 | 47 | 0.260 |
Why?
|
Child, Preschool | 4 | 2021 | 3608 | 0.260 |
Why?
|
Systems Analysis | 2 | 2021 | 17 | 0.260 |
Why?
|
Oregon | 2 | 2022 | 26 | 0.250 |
Why?
|
Community Networks | 2 | 2021 | 29 | 0.250 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2004 | 23 | 0.240 |
Why?
|
Pancreatic Neoplasms | 1 | 2009 | 645 | 0.240 |
Why?
|
Health Personnel | 2 | 2019 | 202 | 0.240 |
Why?
|
Proportional Hazards Models | 6 | 2020 | 857 | 0.230 |
Why?
|
Reproducibility of Results | 5 | 2020 | 2699 | 0.230 |
Why?
|
Rural Population | 1 | 2024 | 136 | 0.230 |
Why?
|
Tool Use Behavior | 1 | 2023 | 12 | 0.230 |
Why?
|
Drug Utilization | 3 | 2016 | 65 | 0.230 |
Why?
|
Hip Fractures | 1 | 2023 | 45 | 0.230 |
Why?
|
Biological Transport | 1 | 2024 | 396 | 0.230 |
Why?
|
Cholesterol | 3 | 2019 | 356 | 0.230 |
Why?
|
Activities of Daily Living | 4 | 2017 | 202 | 0.230 |
Why?
|
Osteoporotic Fractures | 1 | 2023 | 38 | 0.220 |
Why?
|
Insurance | 1 | 2022 | 10 | 0.220 |
Why?
|
Washington | 1 | 2022 | 48 | 0.220 |
Why?
|
Patient Care Team | 2 | 2010 | 280 | 0.220 |
Why?
|
New York | 1 | 2022 | 69 | 0.220 |
Why?
|
Patient Participation | 2 | 2016 | 216 | 0.220 |
Why?
|
Cystitis | 1 | 2002 | 13 | 0.210 |
Why?
|
Diabetic Neuropathies | 2 | 2016 | 40 | 0.210 |
Why?
|
Waiting Lists | 2 | 2020 | 175 | 0.210 |
Why?
|
Postural Balance | 1 | 2021 | 42 | 0.210 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 156 | 0.210 |
Why?
|
Health Information Exchange | 1 | 2021 | 12 | 0.210 |
Why?
|
Accelerometry | 2 | 2021 | 36 | 0.210 |
Why?
|
Awards and Prizes | 1 | 2022 | 36 | 0.210 |
Why?
|
Medical Informatics | 1 | 2022 | 47 | 0.210 |
Why?
|
Hyperglycemia | 5 | 2014 | 176 | 0.200 |
Why?
|
Prospective Studies | 6 | 2023 | 4194 | 0.200 |
Why?
|
Urinary Tract Infections | 1 | 2002 | 72 | 0.200 |
Why?
|
Cultural Competency | 1 | 2021 | 21 | 0.200 |
Why?
|
Medical Overuse | 2 | 2018 | 36 | 0.200 |
Why?
|
Walking | 1 | 2021 | 86 | 0.200 |
Why?
|
Communication | 2 | 2016 | 438 | 0.200 |
Why?
|
Cooperative Behavior | 2 | 2016 | 174 | 0.200 |
Why?
|
Fungemia | 1 | 2020 | 15 | 0.190 |
Why?
|
Ambulatory Care | 1 | 2002 | 180 | 0.190 |
Why?
|
Anticholesteremic Agents | 1 | 2001 | 137 | 0.190 |
Why?
|
Disease Progression | 4 | 2020 | 1531 | 0.190 |
Why?
|
Mesalamine | 1 | 2021 | 88 | 0.190 |
Why?
|
Body Temperature | 1 | 2020 | 124 | 0.180 |
Why?
|
Pilot Projects | 2 | 2016 | 837 | 0.180 |
Why?
|
Infant, Newborn | 2 | 2020 | 2369 | 0.180 |
Why?
|
Poverty Areas | 1 | 2020 | 37 | 0.180 |
Why?
|
Insurance Claim Review | 1 | 2020 | 41 | 0.180 |
Why?
|
Bacteremia | 1 | 2020 | 99 | 0.180 |
Why?
|
Health Care Surveys | 5 | 2019 | 277 | 0.180 |
Why?
|
Diabetic Angiopathies | 2 | 2017 | 62 | 0.180 |
Why?
|
Fever | 1 | 2020 | 125 | 0.180 |
Why?
|
State Health Plans | 1 | 2019 | 14 | 0.180 |
Why?
|
Phenotype | 3 | 2021 | 2375 | 0.180 |
Why?
|
Diabetic Nephropathies | 2 | 2016 | 248 | 0.180 |
Why?
|
Liver Transplantation | 1 | 2007 | 1263 | 0.180 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 62 | 0.180 |
Why?
|
Antihypertensive Agents | 2 | 2016 | 521 | 0.180 |
Why?
|
Intention to Treat Analysis | 1 | 2019 | 72 | 0.180 |
Why?
|
Confidence Intervals | 2 | 2009 | 228 | 0.170 |
Why?
|
Piperidines | 1 | 2021 | 181 | 0.170 |
Why?
|
Sulfonylurea Compounds | 2 | 2023 | 64 | 0.170 |
Why?
|
Withholding Treatment | 1 | 2019 | 111 | 0.170 |
Why?
|
Insulin, Isophane | 1 | 2018 | 2 | 0.170 |
Why?
|
Insulin Detemir | 1 | 2018 | 3 | 0.170 |
Why?
|
Insulin Glargine | 1 | 2018 | 9 | 0.170 |
Why?
|
Early Medical Intervention | 1 | 2018 | 18 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 241 | 0.170 |
Why?
|
Endometrial Neoplasms | 1 | 2021 | 191 | 0.170 |
Why?
|
Psychomotor Performance | 1 | 2021 | 492 | 0.160 |
Why?
|
Machine Learning | 1 | 2020 | 232 | 0.160 |
Why?
|
Sensitivity and Specificity | 3 | 2017 | 1987 | 0.160 |
Why?
|
Exercise | 1 | 2021 | 315 | 0.160 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 161 | 0.160 |
Why?
|
Blood Specimen Collection | 2 | 2014 | 27 | 0.160 |
Why?
|
Hospital Mortality | 1 | 2020 | 347 | 0.160 |
Why?
|
Pyrimidines | 1 | 2021 | 370 | 0.160 |
Why?
|
Sex Factors | 3 | 2018 | 1053 | 0.160 |
Why?
|
Cost Savings | 1 | 2017 | 66 | 0.150 |
Why?
|
Social Support | 2 | 2023 | 193 | 0.150 |
Why?
|
Medically Uninsured | 2 | 2014 | 58 | 0.150 |
Why?
|
Multivariate Analysis | 3 | 2015 | 997 | 0.150 |
Why?
|
Health Promotion | 1 | 2019 | 160 | 0.150 |
Why?
|
Gangrene | 1 | 2016 | 7 | 0.150 |
Why?
|
Models, Statistical | 3 | 2020 | 574 | 0.150 |
Why?
|
Smoking Cessation | 1 | 2019 | 230 | 0.150 |
Why?
|
Veterans Health | 1 | 2016 | 15 | 0.150 |
Why?
|
Prognosis | 4 | 2020 | 3669 | 0.150 |
Why?
|
Osteomyelitis | 1 | 2016 | 54 | 0.150 |
Why?
|
Glycemic Index | 1 | 2016 | 10 | 0.140 |
Why?
|
Perception | 2 | 2008 | 167 | 0.140 |
Why?
|
Motivation | 4 | 2021 | 287 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 589 | 0.140 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 411 | 0.140 |
Why?
|
Coronary Disease | 1 | 2017 | 261 | 0.140 |
Why?
|
Cardiovascular Agents | 1 | 2016 | 56 | 0.140 |
Why?
|
Protein Precursors | 2 | 2013 | 143 | 0.140 |
Why?
|
Cognitive Dysfunction | 1 | 2018 | 132 | 0.140 |
Why?
|
Drug Utilization Review | 1 | 2015 | 14 | 0.140 |
Why?
|
Organizational Culture | 1 | 2016 | 33 | 0.140 |
Why?
|
Pandemics | 1 | 2022 | 739 | 0.140 |
Why?
|
Patient Preference | 1 | 2016 | 104 | 0.140 |
Why?
|
Motor Activity | 1 | 2018 | 327 | 0.130 |
Why?
|
Skilled Nursing Facilities | 1 | 2016 | 41 | 0.130 |
Why?
|
Long-Term Care | 1 | 2016 | 60 | 0.130 |
Why?
|
Philippines | 1 | 2015 | 23 | 0.130 |
Why?
|
Guidelines as Topic | 1 | 2016 | 162 | 0.130 |
Why?
|
Observational Studies as Topic | 1 | 2015 | 48 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 1305 | 0.130 |
Why?
|
Anthropometry | 1 | 2014 | 74 | 0.130 |
Why?
|
Pregnancy | 1 | 2022 | 2885 | 0.130 |
Why?
|
Atherosclerosis | 1 | 2017 | 243 | 0.120 |
Why?
|
Specimen Handling | 1 | 2014 | 98 | 0.120 |
Why?
|
Colitis, Ulcerative | 1 | 2021 | 708 | 0.120 |
Why?
|
Statistics as Topic | 1 | 2015 | 237 | 0.120 |
Why?
|
Computer Simulation | 2 | 2021 | 1077 | 0.120 |
Why?
|
Carrier State | 1 | 2013 | 39 | 0.120 |
Why?
|
Bacteriological Techniques | 1 | 2013 | 39 | 0.120 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2013 | 30 | 0.120 |
Why?
|
Heart Failure | 2 | 2020 | 1196 | 0.120 |
Why?
|
Calcitonin | 1 | 2013 | 38 | 0.120 |
Why?
|
Patient Access to Records | 1 | 2013 | 2 | 0.120 |
Why?
|
Cholesterol, LDL | 1 | 2015 | 222 | 0.120 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 80 | 0.120 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 73 | 0.110 |
Why?
|
Intention | 1 | 2013 | 51 | 0.110 |
Why?
|
Demography | 1 | 2013 | 177 | 0.110 |
Why?
|
Remission Induction | 1 | 2014 | 722 | 0.110 |
Why?
|
Musculoskeletal Pain | 1 | 2012 | 10 | 0.110 |
Why?
|
Survival Rate | 2 | 2014 | 1856 | 0.110 |
Why?
|
Risk | 4 | 2016 | 673 | 0.110 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 362 | 0.110 |
Why?
|
Brain | 2 | 2018 | 2211 | 0.110 |
Why?
|
Trust | 1 | 2013 | 95 | 0.110 |
Why?
|
Neoplasms | 2 | 2017 | 2889 | 0.110 |
Why?
|
Linear Models | 1 | 2013 | 419 | 0.110 |
Why?
|
Glomerular Filtration Rate | 1 | 2013 | 384 | 0.100 |
Why?
|
United Kingdom | 1 | 2012 | 164 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Protein 5 | 1 | 2011 | 7 | 0.100 |
Why?
|
Career Choice | 1 | 2013 | 139 | 0.100 |
Why?
|
Blood Pressure Determination | 1 | 2012 | 90 | 0.100 |
Why?
|
Health Status Indicators | 1 | 2011 | 105 | 0.100 |
Why?
|
Staphylococcal Infections | 1 | 2013 | 255 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2434 | 0.100 |
Why?
|
Mental Health | 1 | 2012 | 160 | 0.100 |
Why?
|
Sodium | 2 | 2022 | 340 | 0.100 |
Why?
|
Neoplasm Staging | 2 | 2021 | 1932 | 0.100 |
Why?
|
Cost Sharing | 1 | 2010 | 14 | 0.100 |
Why?
|
Medical Informatics Applications | 1 | 2010 | 9 | 0.100 |
Why?
|
Cost Control | 1 | 2010 | 44 | 0.090 |
Why?
|
Survival Analysis | 3 | 2019 | 1536 | 0.090 |
Why?
|
Massachusetts | 2 | 2014 | 33 | 0.090 |
Why?
|
Principal Component Analysis | 1 | 2010 | 155 | 0.090 |
Why?
|
Budgets | 1 | 2009 | 10 | 0.090 |
Why?
|
Osteosarcoma | 1 | 2011 | 158 | 0.090 |
Why?
|
Government Programs | 1 | 2009 | 8 | 0.090 |
Why?
|
Secondary Prevention | 1 | 2010 | 162 | 0.090 |
Why?
|
Primary Prevention | 1 | 2010 | 85 | 0.090 |
Why?
|
Prejudice | 1 | 2009 | 49 | 0.090 |
Why?
|
Triglycerides | 2 | 2017 | 232 | 0.090 |
Why?
|
Glucose | 2 | 2022 | 637 | 0.090 |
Why?
|
Endosonography | 1 | 2009 | 96 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 508 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2009 | 141 | 0.080 |
Why?
|
Bone Neoplasms | 1 | 2011 | 322 | 0.080 |
Why?
|
Social Identification | 1 | 2008 | 24 | 0.080 |
Why?
|
Personnel Management | 1 | 2008 | 7 | 0.080 |
Why?
|
Interview, Psychological | 1 | 2008 | 69 | 0.080 |
Why?
|
Sample Size | 1 | 2008 | 130 | 0.080 |
Why?
|
Peer Group | 1 | 2008 | 72 | 0.080 |
Why?
|
Los Angeles | 1 | 2007 | 28 | 0.080 |
Why?
|
Cost Allocation | 1 | 2007 | 5 | 0.080 |
Why?
|
Midwestern United States | 1 | 2007 | 76 | 0.080 |
Why?
|
Specialization | 2 | 2008 | 65 | 0.080 |
Why?
|
Parents | 1 | 2010 | 269 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2010 | 301 | 0.080 |
Why?
|
Poverty | 2 | 2019 | 171 | 0.080 |
Why?
|
Reimbursement, Incentive | 1 | 2007 | 37 | 0.080 |
Why?
|
Health Behavior | 2 | 2008 | 183 | 0.080 |
Why?
|
Policy Making | 1 | 2007 | 62 | 0.080 |
Why?
|
Patient Compliance | 1 | 2008 | 226 | 0.080 |
Why?
|
Medicine | 2 | 2008 | 89 | 0.070 |
Why?
|
Cultural Diversity | 1 | 2007 | 51 | 0.070 |
Why?
|
Leadership | 1 | 2008 | 134 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 509 | 0.070 |
Why?
|
Colorectal Neoplasms | 1 | 2013 | 924 | 0.070 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2021 | 929 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2007 | 169 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2021 | 1801 | 0.070 |
Why?
|
Fluoroquinolones | 1 | 2005 | 22 | 0.070 |
Why?
|
Life Change Events | 1 | 2005 | 48 | 0.060 |
Why?
|
Resource Allocation | 2 | 2019 | 65 | 0.060 |
Why?
|
Illinois | 1 | 2006 | 461 | 0.060 |
Why?
|
Synaptic Membranes | 1 | 2004 | 14 | 0.060 |
Why?
|
Niemann-Pick Diseases | 1 | 2004 | 6 | 0.060 |
Why?
|
Friends | 1 | 2023 | 17 | 0.060 |
Why?
|
Family Practice | 1 | 2004 | 84 | 0.060 |
Why?
|
Cognition | 2 | 2018 | 570 | 0.060 |
Why?
|
Health Resources | 1 | 2004 | 76 | 0.060 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2022 | 9 | 0.060 |
Why?
|
Point-of-Care Systems | 1 | 2023 | 141 | 0.050 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2022 | 48 | 0.050 |
Why?
|
Bone Density | 1 | 2023 | 209 | 0.050 |
Why?
|
Urinalysis | 1 | 2002 | 33 | 0.050 |
Why?
|
United States Dept. of Health and Human Services | 1 | 2011 | 5 | 0.050 |
Why?
|
Microsatellite Instability | 1 | 2021 | 40 | 0.050 |
Why?
|
Vulnerable Populations | 2 | 2014 | 76 | 0.050 |
Why?
|
Decision Trees | 1 | 2021 | 63 | 0.050 |
Why?
|
Deprescriptions | 1 | 2021 | 5 | 0.050 |
Why?
|
Jurisprudence | 1 | 2021 | 25 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2004 | 377 | 0.050 |
Why?
|
Equipment Design | 1 | 2012 | 405 | 0.050 |
Why?
|
Models, Economic | 1 | 2021 | 60 | 0.050 |
Why?
|
Blood Culture | 1 | 2020 | 11 | 0.050 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 113 | 0.050 |
Why?
|
Exercise Test | 1 | 2021 | 164 | 0.050 |
Why?
|
Antipyretics | 1 | 2020 | 2 | 0.050 |
Why?
|
Health Education | 1 | 2011 | 100 | 0.050 |
Why?
|
Nerve Tissue Proteins | 1 | 2004 | 503 | 0.050 |
Why?
|
Quinolines | 1 | 2021 | 95 | 0.050 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 28 | 0.050 |
Why?
|
Length of Stay | 1 | 2004 | 697 | 0.050 |
Why?
|
Infliximab | 1 | 2021 | 151 | 0.050 |
Why?
|
Troponin | 1 | 2020 | 24 | 0.050 |
Why?
|
Regression Analysis | 1 | 2002 | 595 | 0.050 |
Why?
|
Bilirubin | 1 | 2020 | 124 | 0.050 |
Why?
|
Carboplatin | 1 | 2021 | 286 | 0.050 |
Why?
|
Lactic Acid | 1 | 2020 | 90 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2004 | 672 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2015 | 912 | 0.050 |
Why?
|
Patient Acuity | 1 | 2019 | 32 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 87 | 0.050 |
Why?
|
Intra-Aortic Balloon Pumping | 1 | 2020 | 78 | 0.040 |
Why?
|
Research Design | 1 | 2023 | 594 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 429 | 0.040 |
Why?
|
Paclitaxel | 1 | 2021 | 460 | 0.040 |
Why?
|
Creatinine | 1 | 2020 | 337 | 0.040 |
Why?
|
Protective Factors | 1 | 2018 | 22 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2016 | 1796 | 0.040 |
Why?
|
Age Distribution | 2 | 2012 | 204 | 0.040 |
Why?
|
Population Health | 1 | 2019 | 33 | 0.040 |
Why?
|
Biological Products | 1 | 2021 | 143 | 0.040 |
Why?
|
Systole | 1 | 2018 | 129 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2011 | 2260 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 893 | 0.040 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2020 | 139 | 0.040 |
Why?
|
Glycoproteins | 2 | 2013 | 234 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2018 | 203 | 0.040 |
Why?
|
Propensity Score | 1 | 2018 | 136 | 0.040 |
Why?
|
Apolipoproteins E | 1 | 2018 | 129 | 0.040 |
Why?
|
Organ Size | 1 | 2018 | 363 | 0.040 |
Why?
|
Pedigree | 1 | 2019 | 966 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 247 | 0.040 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2016 | 8 | 0.040 |
Why?
|
Antidepressive Agents | 1 | 2017 | 106 | 0.040 |
Why?
|
Diet Therapy | 1 | 2016 | 20 | 0.040 |
Why?
|
Hospitals, Veterans | 1 | 2016 | 17 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2016 | 81 | 0.040 |
Why?
|
Microvessels | 1 | 2016 | 70 | 0.040 |
Why?
|
Neuropsychological Tests | 1 | 2018 | 502 | 0.040 |
Why?
|
Drug Monitoring | 1 | 2016 | 118 | 0.030 |
Why?
|
Mortality | 1 | 2017 | 148 | 0.030 |
Why?
|
Medicare Part A | 1 | 2015 | 3 | 0.030 |
Why?
|
Medicare Part B | 1 | 2015 | 3 | 0.030 |
Why?
|
Life Style | 1 | 2016 | 188 | 0.030 |
Why?
|
Qualitative Research | 1 | 2016 | 256 | 0.030 |
Why?
|
United States Health Resources and Services Administration | 1 | 2014 | 2 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2015 | 51 | 0.030 |
Why?
|
Idaho | 1 | 2014 | 7 | 0.030 |
Why?
|
Urine Specimen Collection | 1 | 2014 | 4 | 0.030 |
Why?
|
Neurons | 1 | 2004 | 1545 | 0.030 |
Why?
|
Pennsylvania | 1 | 2014 | 75 | 0.030 |
Why?
|
Consensus Sequence | 1 | 1993 | 64 | 0.030 |
Why?
|
Epidemiological Monitoring | 1 | 2013 | 39 | 0.030 |
Why?
|
Saliva | 1 | 2014 | 122 | 0.030 |
Why?
|
Indians, North American | 1 | 2013 | 48 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2007 | 2881 | 0.030 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2013 | 36 | 0.030 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1993 | 135 | 0.030 |
Why?
|
Genotype | 1 | 2018 | 1850 | 0.030 |
Why?
|
Personnel Turnover | 1 | 2013 | 7 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2013 | 60 | 0.030 |
Why?
|
Models, Organizational | 1 | 2013 | 46 | 0.030 |
Why?
|
Hydrocortisone | 1 | 2014 | 298 | 0.030 |
Why?
|
Educational Status | 1 | 2013 | 187 | 0.030 |
Why?
|
Respiratory Tract Infections | 1 | 2013 | 104 | 0.030 |
Why?
|
Sickness Impact Profile | 1 | 2012 | 27 | 0.030 |
Why?
|
Prediabetic State | 1 | 2012 | 39 | 0.030 |
Why?
|
Infection Control | 1 | 2013 | 115 | 0.030 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 142 | 0.030 |
Why?
|
Cross Infection | 1 | 2013 | 141 | 0.030 |
Why?
|
Sex Distribution | 1 | 2012 | 173 | 0.030 |
Why?
|
Mice | 3 | 2011 | 11313 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2014 | 486 | 0.030 |
Why?
|
Proxy | 1 | 2011 | 24 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2011 | 69 | 0.030 |
Why?
|
Algorithms | 2 | 2011 | 1828 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 859 | 0.020 |
Why?
|
Holistic Health | 1 | 2010 | 8 | 0.020 |
Why?
|
Self Report | 1 | 2012 | 287 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 234 | 0.020 |
Why?
|
Sepsis | 1 | 2013 | 304 | 0.020 |
Why?
|
Down-Regulation | 1 | 2011 | 504 | 0.020 |
Why?
|
Chronic Pain | 1 | 2011 | 145 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 790 | 0.020 |
Why?
|
Time Management | 1 | 2008 | 9 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2008 | 117 | 0.020 |
Why?
|
Employee Incentive Plans | 1 | 2008 | 4 | 0.020 |
Why?
|
Personnel Loyalty | 1 | 2008 | 4 | 0.020 |
Why?
|
Body Weight | 1 | 2009 | 459 | 0.020 |
Why?
|
Professional Autonomy | 1 | 2008 | 41 | 0.020 |
Why?
|
Staff Development | 1 | 2008 | 21 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 1168 | 0.020 |
Why?
|
Models, Psychological | 1 | 2008 | 157 | 0.020 |
Why?
|
Cell Movement | 1 | 2011 | 756 | 0.020 |
Why?
|
Rats | 1 | 1993 | 3984 | 0.020 |
Why?
|
Workload | 1 | 2008 | 128 | 0.020 |
Why?
|
Urban Population | 1 | 2008 | 213 | 0.020 |
Why?
|
Retreatment | 1 | 2006 | 107 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2006 | 73 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2006 | 95 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 3347 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2008 | 222 | 0.020 |
Why?
|
Patient Selection | 1 | 2009 | 685 | 0.020 |
Why?
|
Social Behavior | 1 | 2008 | 294 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 1381 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 2421 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2011 | 1571 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2005 | 71 | 0.020 |
Why?
|
Apoptosis | 1 | 2011 | 1678 | 0.020 |
Why?
|
Disks Large Homolog 4 Protein | 1 | 2004 | 7 | 0.020 |
Why?
|
Guanylate Kinases | 1 | 2004 | 12 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2004 | 133 | 0.010 |
Why?
|
Vesicular Transport Proteins | 1 | 2004 | 63 | 0.010 |
Why?
|
Cytosol | 1 | 2004 | 189 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2004 | 229 | 0.010 |
Why?
|
Astrocytes | 1 | 2004 | 139 | 0.010 |
Why?
|
Dendrites | 1 | 2004 | 99 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2004 | 378 | 0.010 |
Why?
|
Fibroblasts | 1 | 2004 | 729 | 0.010 |
Why?
|
Animals | 3 | 2011 | 26518 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2004 | 1752 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2004 | 2810 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2004 | 1194 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2004 | 3087 | 0.010 |
Why?
|
Gene Conversion | 1 | 1993 | 25 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1993 | 173 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1993 | 157 | 0.010 |
Why?
|
Gene Library | 1 | 1993 | 130 | 0.010 |
Why?
|
Codon | 1 | 1993 | 124 | 0.010 |
Why?
|
Dogs | 1 | 1993 | 684 | 0.010 |
Why?
|
DNA Primers | 1 | 1993 | 542 | 0.010 |
Why?
|
Swine | 1 | 1993 | 554 | 0.010 |
Why?
|
Primates | 1 | 1993 | 151 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1993 | 927 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 1993 | 1047 | 0.010 |
Why?
|
Skin | 1 | 1993 | 554 | 0.010 |
Why?
|
Base Sequence | 1 | 1993 | 2329 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1993 | 3029 | 0.010 |
Why?
|
DNA | 1 | 1993 | 1293 | 0.000 |
Why?
|